

# Financial Tear Sheet

## Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek's two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

## Stock Information

### PRTK (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	<b>\$19.45</b>
Change (%)	<b>▼ 0.25 (1.27%)</b>
Volume	245,891
52 Week Low	\$9.80
Market Cap	\$539,955,107
Rolling EPS	-3.82
PE Ratio	N/A
Shares Outstanding	27,761,188
Data as of 08/18/17 4:00 p.m. ET	



## Recent Paratek Pharmaceuticals News & Events

08/08/17 - 8:00 a.m.

Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference

08/02/17 - 7:00 a.m.

Paratek Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results and Provides Clinical Update

08/01/17 - 8:01 a.m.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
08/04/17	8-K
08/02/17	10-Q
07/21/17	4
07/21/17	4

## Management

Randy Brenner Senior Vice President -  
Regulatory, Quality and  
Technical Operations

Jason Burdette Vice President -  
Technical Operations

Jeanne Jew Senior Vice President -  
Business Development

Raj Padmanabhan Vice President -  
Information Technology

Regina Paglia Senior Vice President -  
Human Resources

Susan Perkins,  
J.D. Vice President -  
Intellectual Property

Evan Tzanis Senior Vice President -  
Clinical Development &  
Clinical Operations

Michael F. Bigham Chief Executive Officer  
and Chairman of the  
Board

Evan Loh, M.D.     President, Chief  
Operating Officer and  
Chief Medical Officer

William Haskel     General Counsel and  
Corporate Secretary

Douglas W. Pagán Chief Financial Officer

Adam Woodrow     Chief Commercial Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.